None
EN
CytoMed Therapeutics Limited (GDTC) Q2 2025 Earnings Call Prepared Remarks Transcript
[]
All Articles on Seeking Alpha
I will now give you a broad overview of the 6 months ended 30th June 2025 financial performance.
Our revenue increased by 100% to SGD 156,000 for the 6 months ended 30th June 2025.
We reported a net loss of $2.05 million in 2025.
Loss per share was $0.19 for 6 months ended 30th June 2025.
The table shows the financial performance for the 6 months ended 30th June 2024 and 2025.